77 patients with unresectable pancreatic cancer treated with SABR (25 Gy × 1 Fc).
Effective for LC. Should be used with rigorous quality assurance to reduce complications. Distant metastases account for the vast majority of mortality.
24 patients treated with SABR adjuvantly after surgical resection.
Freedom from local progression was 66% at one year and median OS was 26.7 months. No incidence of grade 3 or 4 toxicity. Shorter treatment course allowed timely initiation of systemic chemotherapy.